Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 31.0 kDa. The protein migrates as 33-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, His,Avitag (Cat. No. TIT-C82E3) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, His,Avitag (Cat. No. TIT-C82E3) with a linear range of 4-125 ng/mL (QC tested).
Immobilized Anti-TIGIT Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, His,Avitag (Cat. No. TIT-C82E3) with a linear range of 0.06-2 ng/mL (Routinely tested).
Price(USD) : $360.00
Price(USD) : $1420.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vibostolimab | MK-7684 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis | Details |
Domvanalimab | GS-0154; AB-154 | Phase 3 Clinical | Abmuno Therapeutics LLC | Urinary Bladder Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lung Neoplasms; Esophageal adenocarcinoma; Cholangiocarcinoma; Liver Neoplasms; Microsatellite instability-high cancer; Glioblastoma; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Biliary Tract Neoplasms | Details |
Tiragolumab | RG-6058; MTIG-7192A; RO-7092284 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Squamous Cell; Carcinoma, Medullary; Chordoma; Lymphoma, Follicular; Sarcoma; Colorectal Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Multiple Myeloma; Mouth Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Hemangioendothelioma, Epithelioid; Stomach Neoplasms; Teratoma; Liver Neoplasms; Lymphoma, B-Cell; Head and Neck Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Solid tumours; Rectal Neoplasms; Rhabdoid Tumor; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Glioblastoma | Details |
Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Cholangiocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Hematologic Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Ovarian Neoplasms | Details |
Rilvegostomig | AZD-2936 | Phase 3 Clinical | Astrazeneca Plc | Biliary Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Belrestotug | EOS-448; EOS-884448; GSK-4428859; GSK-4428859A | Phase 3 Clinical | Iteos | Solid tumours; Head and Neck Neoplasms; Neoplasms; Multiple Myeloma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
HL-301 | HL-301 | Phase 3 Clinical | Hanmi Pharmaceutical Co Ltd | Radiation Pneumonitis; Acute Bronchitis; Pulmonary Disease, Chronic Obstructive; Lung Neoplasms | Details |
Ociperlimab | BGB-A1217 | Phase 3 Clinical | BeOne Medicines Ltd | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Etigilimab | OMP-313M32 | Phase 2 Clinical | Oncomed Pharmaceuticals Inc | Solid tumours; Ovarian Neoplasms; Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Neoplasm Metastasis | Details |
Renvistobart | BMS-986207; ONO-4686 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ZG-005 | ZG-005 | Phase 2 Clinical | Gensun Biopharma Inc | Solid tumours; Carcinoma, Neuroendocrine; Lymphoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
AK-130 | AK-130 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
HB-0036 | HB-0036 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
PM-1022 | PM-1022 | Phase 2 Clinical | Neoplasms | Details | |
Lancastotug | AK-127 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
HB0030 | HB-0030 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
HLX-53 | HLX-53; HLX53 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Lymphoma; Carcinoma, Hepatocellular | Details |
JS-006 | JS-006; TAB-006; CHS-006 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
PM-1009 | PM1009 | Phase 2 Clinical | Liver Neoplasms; Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular | Details | |
Dargistotug | M-6223; M6223 | Phase 2 Clinical | Emd Serono Research & Development Institute Inc | Solid tumours; Carcinoma, Transitional Cell | Details |
DW-2008 | DW-2008; DW-2008S | Phase 1 Clinical | Dong Wha Pharm Co Ltd | Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma | Details |
Tamgiblimab | IBI-939 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms; Lung Neoplasms | Details |
COM-902 | COM-902 | Phase 1 Clinical | Compugen Ltd | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Colorectal Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) | LP-010 | Phase 1 Clinical | Lepu Biopharma Co Ltd | Solid tumours | Details |
ASP-8374 | ASP-8374; PTZ-201 | Phase 1 Clinical | Potenza Therapeutics, Astellas Pharma Inc | Solid tumours; Glioblastoma | Details |
BMS-986442 | AGEN-1777; BMS-986442; BMS-986-442 | Phase 1 Clinical | Agenus Inc | Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ZGGS-15 | ZGGS15; ZGGS-15 | Phase 1 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BC008-1A | BC008-1A | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
PM-1021 | PM1021 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
BAT-6005 | BAT-6005 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
Ralzapastotug | AB-308 | Phase 1 Clinical | Arcus Biosciences Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.